RT Journal Article
T1 Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.
A1 Mukama, Trasias
A1 Fortner, Renée Turzanski
A1 Katzke, Verena
A1 Hynes, Lucas Cory
A1 Petrera, Agnese
A1 Hauck, Stefanie M
A1 Johnson, Theron
A1 Schulze, Matthias
A1 Schiborn, Catarina
A1 Rostgaard-Hansen, Agnetha Linn
A1 Tjønneland, Anne
A1 Overvad, Kim
A1 Sanchez-Perez, Maria-Jose
A1 Crous-Bou, Marta
A1 Chirlaque, María-Dolores
A1 Amiano, Pilar
A1 Ardanaz, Eva
A1 Watts, Eleanor L
A1 Travis, Ruth C
A1 Sacerdote, Carlotta
A1 Grioni, Sara
A1 Masala, Giovanna
A1 Signoriello, Simona
A1 Tumino, Rosario
A1 Gram, Inger T
A1 Sandanger, Torkjel M
A1 Sartor, Hanna
A1 Lundin, Eva
A1 Idahl, Annika
A1 Heath, Alicia K
A1 Dossus, Laure
A1 Weiderpass, Elisabete
A1 Kaaks, Rudolf
A2 https://www.nature.com/articles/s41416-021-01697-z, 
AB CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9-18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0-9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
PB Nature
YR 2022
FD 2022-01-14
LK http://hdl.handle.net/10668/19522
UL http://hdl.handle.net/10668/19522
LA en
NO Mukama T, Fortner RT, Katzke V, Hynes LC, Petrera A, Hauck SM, et al. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. Br J Cancer. 2022 May;126(9):1301-1309
DS RISalud
RD Apr 9, 2025